The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy? Abstract The development of tirzepatide, a first in class dual glucose dependent insulinotropic polypeptide and glucagon like peptide 1 receptor agonist, represents a potentially transformative advance in the management of type 2 diabetes and obesity. By simultaneously targeting
Tag: incretin pathways
